Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542241 | 0.91 | CYP2C9 (0.42) | CYP2C9KCNH2MAPK1LIPGMET | |
| SCHEMBL4396394 | 0.86 | CYP2C9 (0.42) | CYP2C9KCNH2MAPK1LIPGMET | |
| SCHEMBL5532693 | 0.85 | EGLN1 (0.39) | CYP2C9KCNH2P2RX7 | |
| SCHEMBL5643962 | 0.84 | MAPT (0.37) | DPP4SMN1; SMN2P2RX7POLB | |
| SCHEMBL5537855 | 0.83 | KCNH2 (0.54) | CYP2C9KCNH2LIPGKCNE1CCR1 | |
| SCHEMBL4393763 | 0.82 | CYP2C9 (0.40) | CYP2C9KCNH2 | |
| SCHEMBL4398101 | 0.81 | CYP2C9 (0.39) | CYP2C9KCNH2MAPK1LIPGMET | |
| SCHEMBL4395092 | 0.81 | CYP2C9 (0.39) | CYP2C9KCNH2MET | |
| SCHEMBL5532945 | 0.81 | GAA (0.48) | CYP2C9KCNH2SMN1; SMN2 | |
| SCHEMBL4397947 | 0.80 | CYP2C9 (0.39) | CYP2C9KCNH2LIPGMETSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192948-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1753767-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118589-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267132-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TOP1, APOBEC3C | CYP2C9 237/4885KCNH2 3080/4885DPP4 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.